FDA approves first biosimilar for the treatment of cancer
The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.
Source: Food and Drug Administration - Category: American Health Source Type: news
More News: American Health | Avastin | Cancer | Cancer & Oncology | Food and Drug Administration (FDA)